222 related articles for article (PubMed ID: 29425358)
1. Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination.
Machalek DA; Garland SM; Brotherton JML; Bateson D; McNamee K; Stewart M; Rachel Skinner S; Liu B; Cornall AM; Kaldor JM; Tabrizi SN
J Infect Dis; 2018 Apr; 217(10):1590-1600. PubMed ID: 29425358
[TBL] [Abstract][Full Text] [Related]
2. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017.
Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Regan DG; Hocking JS; Garland SM; Cornall AM; Atchison S; Bradshaw CS; McNulty A; Owen L; Marshall L; Russell DB; Kaldor JM; Chen MY
Vaccine; 2019 Oct; 37(46):6907-6914. PubMed ID: 31562001
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
6. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.
Cameron RL; Kavanagh K; Pan J; Love J; Cuschieri K; Robertson C; Ahmed S; Palmer T; Pollock KG
Emerg Infect Dis; 2016 Jan; 22(1):56-64. PubMed ID: 26692336
[TBL] [Abstract][Full Text] [Related]
7. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
8. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA
Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743
[TBL] [Abstract][Full Text] [Related]
10. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
11. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
12. Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register.
Brotherton J; Gertig D; Chappell G; Rowlands L; Saville M
Commun Dis Intell Q Rep; 2011 Jun; 35(2):197-201. PubMed ID: 22010515
[TBL] [Abstract][Full Text] [Related]
13. Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs.
Elfström KM; Lazzarato F; Franceschi S; Dillner J; Baussano I
J Infect Dis; 2016 Jan; 213(2):199-205. PubMed ID: 26142436
[TBL] [Abstract][Full Text] [Related]
14. The Australian experience with the human papillomavirus vaccine.
Garland SM
Clin Ther; 2014 Jan; 36(1):17-23. PubMed ID: 24417782
[TBL] [Abstract][Full Text] [Related]
15. Fall in human papillomavirus prevalence following a national vaccination program.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Cummins E; Liu B; Bateson D; McNamee K; Garefalakis M; Garland SM
J Infect Dis; 2012 Dec; 206(11):1645-51. PubMed ID: 23087430
[TBL] [Abstract][Full Text] [Related]
16. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study.
McGregor S; Saulo D; Brotherton JML; Liu B; Phillips S; Skinner SR; Luey M; Oliver L; Stewart M; Tabrizi SN; Garland S; Kaldor JM
Vaccine; 2018 Jul; 36(29):4311-4316. PubMed ID: 29880245
[TBL] [Abstract][Full Text] [Related]
17. The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016.
Mesher D; Panwar K; Thomas SL; Edmundson C; Choi YH; Beddows S; Soldan K
J Infect Dis; 2018 Aug; 218(6):911-921. PubMed ID: 29917082
[TBL] [Abstract][Full Text] [Related]
18. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.
Markowitz LE; Hariri S; Lin C; Dunne EF; Steinau M; McQuillan G; Unger ER
J Infect Dis; 2013 Aug; 208(3):385-93. PubMed ID: 23785124
[TBL] [Abstract][Full Text] [Related]
19. Quadrivalent human papillomavirus vaccination successfully reduces the prevalence of vaccine-targeted genotypes in a young, vaccine-eligible-age sample of Australian females.
Subasinghe AK; Wark JD; Phillips S; Cornall A; Brotherton JML; Garland SM
Sex Health; 2020 Dec; 17(6):510-516. PubMed ID: 33341122
[TBL] [Abstract][Full Text] [Related]
20. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
Donken R; King AJ; Bogaards JA; Woestenberg PJ; Meijer CJLM; de Melker HE
J Infect Dis; 2018 Apr; 217(10):1579-1589. PubMed ID: 29409034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
